We are calling for urgent action to ensure Australian patients do not lose access to Zoladex 3.6mg from 1 November 2026.

Zoladex 3.6mg, also known as goserelin, is used by many Australians as part of treatment for hormone-sensitive breast cancer, endometriosis and other serious medical conditions.

For breast cancer patients, Zoladex can form a critical part of ovarian suppression and ongoing hormone treatment. For endometriosis patients, it can be an important part of managing a painful, chronic and often life-disrupting condition.

This medication is not optional for many people. It is not cosmetic. It is not a convenience medication.

I am a young breast cancer survivor (age: 30), and Zoladex forms part of my ongoing treatment plan. I do not particularly enjoy being jabbed every month with a needle the size of a microchipper. I do not do it for fun, and I certainly do not do it because it is easy.

I do it because ovarian suppression is part of reducing my recurrence risk and giving myself the best possible chance at a long, healthy life.

Cancer patients have already endured enough. Diagnosis, surgery, chemotherapy, radiation, fertility decisions, medical menopause, hot flushes, bone pain, emotional trauma and the constant fear of recurrence are already more than enough to carry.

Endometriosis patients have also had to fight for far too long to be believed, diagnosed, treated and supported.

To then have access to an important medication threatened for commercial reasons is devastating, frightening and unacceptable.

No one should find out through the news that a medication forming part of their treatment plan may be taken away. No patient should be left wondering whether their care will be interrupted. No doctor should be forced into rushed treatment changes because of a corporate decision.

We are asking for:

• AstraZeneca to reverse the discontinuation of Zoladex 3.6mg in Australia, or provide a guaranteed long-term access pathway for patients who need it.
• The Federal Government and PBAC to urgently secure PBS-listed alternatives, including consideration of PBS access to Zoladex 10.8mg for breast cancer patients where clinically appropriate.
• A clear transition plan for all current patients before 1 November 2026, so no patient experiences a gap in ovarian suppression or treatment continuity.
• Transparent communication to patients and clinicians, including clear information about alternatives, access programs, costs and timelines.

A commitment that essential medication access will not be left vulnerable to commercial decisions without proper patient safeguards in place.

Patients deserve certainty.

Cancer patients deserve stability.

Endometriosis patients deserve options.

People already living with serious illness should not have to fight to keep access to medication that helps them manage their condition, reduce risk or maintain quality of life.

I don’t get Zoladex because I am bored and looking for a quirky little monthly hobby. I get it because I had hormone-positive breast cancer. Because my ovaries need to be suppressed. Because recurrence risk is not something I can simply positive-mindset my way out of.

Patients are not profit margins.

Cancer treatment should not come with a corporate plot twist.

We urge AstraZeneca, the PBAC, the Department of Health and the Australian Government to act immediately to protect patients and ensure there is no interruption to care.

Please sign and share this petition to help keep Zoladex 3.6mg available for the Australians who rely on it.